ºÚÁÏÕýÄÜÁ¿

remains the most common cancer in women worldwide and continues to pose a major public health challenge. In 2022, an estimated 2.3 million women were diagnosed and about 670,000 died from the disease globally. Lifestyle factors, including age, obesity, alcohol consumption, tobacco use, postmenopausal hormone therapy and prior radiation exposure, are well-established drivers of risk. New evidence suggests that another, less visible, player may also be at work: the .

in the gut and reproductive tract are increasingly recognized as hidden influencers of hormone regulation, immune homeostasis and cancer biology. By shaping how estrogens are metabolized, how inflammation is controlled and how local tissues develop, these microbial ecosystems may contribute to both the risk and progression of breast cancer.

Therefore, exploring how the gut and reproductive tract microbiomes intersect with hormone regulation and cancer pathways could reveal new avenues for prevention, diagnosis and therapy, and place the microbiome at the center of the conversation about women’s health and breast cancer.

Estrogen Metabolism

The Estrobolome 

The gut microbiome is not only a digestive partner, but also a . A  is diverse and includes bacterial species belonging to the Clostridium, Bacteroides, Eubacterium, Lactobacillus and Ruminococcus genera. Many of these microbes carry genes like β- glucuronidase, β-glucosidase and sulfatase, whose enzyme products metabolize estrogens in ways that keep circulating levels of the hormone in balance. The collection of gut microbial genes capable of metabolizing  is known as the estrobolome.

°Õ³ó±ð  regulates enterohepatic circulation, a process by which estrogens are secreted into the bile and then reabsorbed into the bloodstream, which controls the overall bioavailability of estrogen in the body. Certain gut bacteria, particularly species from the Clostridium, Bacteroides and Escherichia genera, secrete the enzyme , which deconjugates (or reactivates) estrogens that were previously inactivated by the liver. These reactivated estrogens can then bind to estrogen receptors and trigger downstream physiological responses throughout the body.

Estrogen acts as a potent driver of tumor progression in estrogen receptor–positive (ER+) breast cancer, the most common subtype, accounting for roughly 70% of all cases. In these tumors, cells express estrogen receptors (ERα and ERβ) that bind circulating estrogen and activate genes involved in cell proliferation, survival and growth signaling, including the MYC oncogene, CCND1 (cyclin D1), BCL-2 (B-cell leukemia/lymphoma 2) and pS2/TFF1 (trefoil factor family 1). This gene activation increases DNA synthesis and suppresses apoptosis, promoting unchecked cell division.

Dysbiosis and Hormonal Imbalance

When the microbiome becomes disrupted—through factors such as antibiotic use, poor diet, chronic stress and inflammation—a condition known as  can reduce microbial diversity, allowing potentially harmful bacteria to dominate. Such imbalance can alter hormone metabolism and immune signaling, contributing to the development of hormone-driven cancers, including endometrial, ovarian, cervical, prostate and breast cancer.

 at the National Cancer Institute found that postmenopausal women with breast cancer had gut microbiota with reduced diversity and altered composition compared to healthy controls. This decrease in diversity reflects a loss of estrobolome capacity, meaning fewer microbial genes are available to process and reactivate estrogens.

Ultimately, changes in the activity of key enzymes produced by bacteria in the estrobolome, such as β-glucuronidase, β-glucosidase and sulfatase, can shift circulating hormone levels and indirectly influence tumor behavior. When microbial diversity declines, β-glucuronidase activity drops, lowering the proportion of active estrogen available to bind estrogen receptors. This disrupted balance between conjugated (inactive), and unconjugated (active) estrogen may, in turn, promote hormone-driven tumor growth in estrogen receptor–positive breast cancers.

Further supporting the connection between the gut microbiome and estrogen metabolism, researchers have identified specific bacterial families that play a direct role in regulating hormone levels. Members of the Clostridiaceae and Ruminococcaceae families, both rich in β-glucuronidase (β-GUS) encoding genes and key constituents of the estrobolome, have been strongly associated with urinary estrogen levels and overall microbiome richness. These bacteria contribute to estrogen deconjugation within the gut, influencing how much active hormone is reabsorbed into circulation.

Together, these findings demonstrate that the gut microbiota, estrobolome activity and estrogen homeostasis are deeply interconnected. Disruption of this microbial network can alter hormone availability and may contribute to the initiation and progression of hormone-driven cancers, including breast cancer.

Inflammation and Immune Modulation

Microbial Metabolites, Toll-like Receptors and Pro-Inflammatory Cytokines

is another critical link between dysbiosis and cancer. Under normal conditions, in the gut and reproductive tract, commensal microbes constantly interact with the host immune system to maintain equilibrium by stimulating protective immune defenses without triggering chronic inflammation. Microbes can release metabolites and cell wall components, such as lipopolysaccharides (LPS) and peptidoglycans, which enter systemic circulation and engage the host’s (TLRs) on immune and epithelial cells. Activation of TLR signaling triggers downstream cytokine production, such as IL-6, TNF-α and IL-1β, that can modulate inflammation and cell proliferation in distant tissues, including the breast. Similarly, reports that microbial-derived effectors that trigger TLR-mediated immune activation in peripheral tissues contribute to chronic inflammation and a tumor-promoting environment. In the breast, such signaling may enhance , epithelial cell proliferation and immune evasion processes, all of which can accelerate cancer progression.

of beneficial bacteria reduces production of short-chain fatty acids (SCFAs)—key metabolites that normally suppress inflammation and support epithelial integrity. Without these protective compounds, pro-inflammatory cytokines can dominate, establishing a microenvironment that favors tumor growth.

Cancer-Associated Microbial Signatures

In breast cancer specifically, and host–microbe interactions appear to influence both estrogen receptor signaling and immune checkpoint activity, potentially accelerating tumor progression. Evidence from both animal and human studies supports this connection. A  profiled tumor-associated microbiota across multiple cancer types, including breast cancer, and discovered that each cancer harbored a unique microbial signature. For instance, bacteria capable of producing mycothiol, a compound that helps detoxify reactive oxygen species, were enriched in breast cancer subtypes associated with higher oxidative stress.

The researchers also detected bacterial DNA and microbial metabolites within tumor tissue—not necessarily inside the tumor cells themselves, but within the tumor microenvironment. Their findings suggest that bacteria residing within tumors may influence local metabolic and immune conditions, shaping the tumor’s behavior and progression.

Preclinical mouse models echo these findings. show that antibiotic induced gut dysbiosis accelerates mammary tumor growth, in part by weakening anti-tumor immune defenses and altering mammary gland structure in ways that favor carcinogenesis.

Gut-Immune-Breast Crosstalk

Researchers are also beginning to explore whether microbial imbalances that begin locally, such as in the gut or reproductive tract, can influence distant organs like the breast through systemic immune or metabolic signaling. Emerging evidence suggests that microbial activity in the gut may shape immune cell behavior in ways that contribute to cancer risk.

For example, one found that a specific gut microbial biosynthesis pathway was linked to breast cancer risk, and that this association appeared to be mediated by changes in immune cell traits, particularly a subset of CD4+CD8+ T cells involved in inflammatory regulation. While these findings remain preliminary, they highlight a broader concept of gut–immune–breast crosstalk, where microbial metabolites and immune signaling form a communication network that influences breast tissue physiology and disease susceptibility.

This growing body of research strengthens the view that the microbiome functions not just as a local ecosystem, but also as a body-wide endocrine and immune organ—capable of shaping systemic hormone levels, inflammatory tone and, ultimately, cancer risk.

Although direct human data showing reproductive tract inflammation leading to systemic immune changes in breast cancer are still limited, these studies provide plausible mechanistic connections. Microbial imbalances in the vaginal microbiome can trigger localized inflammation and alter mucosal immunity. These changes may extend beyond the reproductive tract through cytokine signaling or immune cell activation, influencing systemic inflammatory tone and, ultimately, breast tissue physiology.

Taken together, current findings suggest that dysbiosis may actively shape, rather than simply accompany, cancer development. By disturbing inflammatory signaling and impairing immune surveillance, microbial imbalance can help create the tumor-promoting microenvironment that fuels breast cancer progression.

Clinical Implications and Future Directions

As research into the human microbiome expands, its potential impact on breast cancer prevention and therapy is becoming clearer. Distinct microbial signatures in the gut and reproductive tract are being investigated as potential  for cancer risk or therapeutic response. For instance, variations in gut bacterial diversity, estrobolome activity and immune-related taxa could inform early detection or help predict how patients respond to hormone-based or immunomodulatory treatments.

At the same time, microbiome-targeted strategies, from diet,  to and even , are being explored as ways to restore microbial balance, reduce inflammation and stabilize hormone metabolism. While still in early stages, these approaches could eventually complement conventional breast cancer therapies by enhancing treatment efficacy, improving immune recovery and minimizing side effects, such as chemotherapy-induced mucositis (inflammation of mucus membranes) or metabolic disturbances.

Despite these advances, several challenges remain. Microbial communities not only in taxonomic composition (which species are present), but also in functional capacity (what metabolic or signaling activities they perform). This variability makes it difficult to define a single “healthy” baseline microbiome or to predict universal therapeutic outcomes. Moreover, most current studies are correlational, so the question of causality—whether dysbiosis drives cancer progression or simply reflects it—remains unresolved.

Translating preclinical insights into human applications also presents obstacles. For example, mouse models differ from humans in hormonal cycles, immune responses and microbiome composition, making direct comparisons complex. Clinical trials must also account for confounding variables, such as diet, antibiotic use and ethnicity, which significantly influence microbial profiles. Future research integrating multi-omics approaches combining metagenomics, metabolomics and immunophenotyping will be crucial to identify actionable microbial signatures and mechanistic links between microbiota and cancer biology.

Despite these obstacles, the field is advancing rapidly. The possibility of harnessing the microbiome for breast cancer prevention and treatment represents a promising frontier in oncology, bridging microbial ecology with molecular medicine. In the future, restoring microbial balance may become as integral to breast cancer care as targeting tumor cells themselves.

---

Learn more about the vaginal microbiome and whether probiotics can be used to boost vaginal health and treat reproductive-tract infections.